FDA says this weight loss drug shortage is over

The FDA has approved a new drug called zolbetuximab designed to attack a novel target that’s in a type of stomach cancer.
Pharmacies currently making copycat versions of Eli Lilly’s tirzepatide face heightened exposure to state enforcement actions ...
This week’s approval expands Seldardsi indications to treat adults with Crohn’s disease and ulcerative colitis.
Oct 23 (Reuters) - Novo Nordisk (NOVOb.CO) on Tuesday asked the U.S. Food and Drug Administration to ban compounding ...
Iterum Therapeutics (ITRM) plc announced that the U.S. Food and Drug Administration has approved Iterum’s new drug application for ...
Despite the benefits of such medicines, like Wegovy, Saxenda and Zepbound, many people who could most benefit from them can’t ...
(The Hill) – Federal regulators shook up the booming weight loss drug marketplace ... Tirzepatide was first approved by the Food and Drug Administration (FDA) in 2022 and has no generic ...
Novo Nordisk NVO has appealed to the U.S. Food and Drug Administration (FDA) to halt the production of compounded versions of its drugs Wegovy and Ozempic by compounding pharmacies. These cheaper ...